Interleukin-17 Inhibitors Patent - Novartis AG

The USPTO granted patent US12600728B2 to NOVARTIS AG, conferring exclusive intellectual property rights to novel pyridine-N oxide substituted 2-formamido acetamide compounds that inhibit Interleukin-17 (IL-17). The patent, with CPC classifications spanning heterocyclic compounds (C07D 487/04, C07D 401/12, C07D 405/12, C07D 413/12, C07D 417/12), covers the compounds, their preparation processes, pharmaceutical compositions, and medicaments.

Pharmaceutical companies developing IL-17 targeted therapies should assess whether their compounds or methods of treatment may encroach on this granted patent. Healthcare providers and clinical investigators researching IL-17 mediated diseases should be aware of potential licensing requirements for therapeutic applications. The 4-claim patent provides Novartis with enforcement mechanisms for unauthorized use of the patented compounds and methods.